Verona Pharma plc
("Verona Pharma" or the "Company")
Secondary listing
to provide trading facility on Xetra Exchange in Germany
12 June 2015, Cardiff –
Verona Pharma plc ('Verona' or 'the Company'), the AIM listed drug
development company focused on first-in-class medicines to treat
respiratory diseases, announces today it has undertaken a secondary
listing on the Xetra exchange, part of the Deutsche Borse in
Germany. The German cusip is ISIN:
GB00B06GSH43 and the symbol is I9S.
Verona Pharma has engaged Oddo
Seydler AG to act as designated sponsor and market maker for the
company’s shares on the Frankfurt
exchange and the electronic Xetra platform. The Company has chosen
to list on the Xetra exchange as a way of further raising its
profile within continental Europe
and to increase the potential for investors in German-speaking
Europe to trade in the Company’s
shares.
-Ends-
For further information please
contact:
Verona Pharma plc |
Tel: +44 (0) 20 7863
3300 |
Jan-Anders Karlsson, CEO |
|
|
|
N+1 Singer |
Tel: +44 (0)20 7496 3000 |
Aubrey Powell / Jen Boorer |
|
|
|
FTI Consulting |
Tel: +44 (0)20 3727 1000 |
Julia Phillips / Simon Conway |
|
Notes to Editors
About Verona Pharma plc
Verona Pharma plc is a UK-based clinical stage biopharmaceutical
company focused on the development of innovative prescription
medicines to treat respiratory diseases with significant unmet
medical needs, such as chronic obstructive pulmonary disease
(COPD), asthma and cystic fibrosis.
Verona Pharma's lead drug, RPL554, is a first-in-class drug
currently in Phase 2 trials as a nebulised treatment for acute
exacerbations of COPD in the hospital setting. The drug is a
dual phosphodiesterase (PDE) 3/4 inhibitor and therefore has both
bronchodilator and anti-inflammatory effects, which are essential
to the improvement of patients with COPD and asthma.
Verona Pharma is also building a broader portfolio of
RPL554-containing products to maximise its benefit to patients and
its value. This includes the very significant markets for
COPD and asthma maintenance therapy. The Company is also
exploring the potential of the drug in different diseases, such as
cystic fibrosis, where it is in pre-clinical testing and has
recently received a Venture and Innovation Award from the UK Cystic
Fibrosis Trust.